IDOV-Immune / ViroMissile - LARVOL DELTA

Safety and Efficacy of Intravenous IDOV-Immune in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=19 | Enrolling by invitation | Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

New P1 trial • Oncology • Solid Tumor

ViroMissile Expands Phase I IDOV-Immune Trial to U.S. Sites Following IND Clearance (GlobeNewswire) - "The Phase I clinical trial (NCT06910657) is evaluating IDOV-Immune in adults with advanced solid tumors. The first patient was dosed at The Alfred Hospital in Melbourne, Victoria, Australia, marking the initiation of clinical evaluation. With U.S. IND acceptance, the trial will soon enroll participants at U.S. sites, including MD Anderson Cancer Center (Houston, TX), START (San Antonio, TX), and Washington University School of Medicine (St. Louis, MO)."

Trial status • Solid Tumor

ViroMissile…announced the initiation of a first-in-human clinical trial evaluating IDOV-Immune, its investigational oncolytic vaccinia virus therapy, in patients with advanced solid tumors (NCT06910657) (GlobeNewswire) - "Additional trial sites across the United States are expected to begin enrolling in 2026, pending clearance of the U.S. IND. The first patient was dosed at The Alfred Hospital in Melbourne, Victoria, Australia."

Trial status • Solid Tumor